Lilly lays out 2-year plan to gain approval for Alzheimer's drug

Eli Lilly will expand an ongoing mid-stage study of its experimental Alzheimer's disease drug donanemab with the aim of obtaining enough data to seek approval from the Food and Drug Administration.